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Abstract: 
Suspensions of spray dried amorphous dispersions are a valuable tool for enhancing the 
exposure of poorly soluble compounds in preclinical animal models.  However, limitations in 
drug supply and time/cost of manufacture in the drug discovery space make it desirable to 
predict the likelihood of obtaining a physically stable (free from detectable crystallization) 
suspension prior to synthetic scale-up and processing of a candidate compound.  Background 
information on this topic is covered in Chapter 1. 
For 33.3% drug load amorphous dispersions in Hydroxypropylmethyl cellulose acetate 
succinate (HPMCAS) suspended in 0.5% methocellulose (MC) + 0.25% sodium lauryl sulfate 
(SLS) + 5 mM HCl, a platform formulation frequently used in discovery, a 2-tiered model can be 
used to correctly predict the physical stability of 22 of 24 model compounds.  First, the model 
considers the humidity adjusted glass transition temperature of the amorphous dispersion 
(Tg,dispersion,100% RH).  For compounds where Tg,dispersion,100% RH is >30 °C,  the amorphous 
dispersion is typically free from crystallization within 3 hours of preparation, which is attributed 
to a decrease in molecular mobility. 3 hours was selected as the timeframe between suspension 
preparation and dosing for the purpose of the present research.  For compounds where 
Tg,dispersion,100% RH is <30 °C, the amorphous dispersion has elevated molecular mobility, and can 
undergo rapid crystallization within a 3 hour dosing window.  For these compounds analysis of 
melting temperature/entropy of fusion (must be <5500 K2*mol/KJ to be predicted stable) and 
molecular weight x LogP (must be >1000 to be predicted stable) can be used to successfully 
predict a 3 hour shelf-life. A decision tree, resulting from this dissertation research, is outlined 
in Figure 1.  
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Figure 1. Decision tree for assessing the physical stability of a model compound spray dried to 
form an amorphous dispersion at 33.3% drug load in HPMCAS and suspended in 0.5% 
methocellulose + 0.25% SLS + 5 mM HCl.   
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Chapter 1: Introduction and Background 
 
 Chapter 1 focuses on providing background rational and design of subsequent chapters. 
The need for solubilization and dissolution rate enhancement in the preclinical space, in order to 
support pharmacology and toxicology animal studies, is first demonstrated.  Next, the chapter 
discusses the available solubilization strategies, potential differences between crystalline and 
amorphous materials, and the benefit and risk associated with utilizing suspensions of 
amorphous solid dispersions for animal studies.  The background further delves into why spray 
drying is the preferred method to prepare ‘suspendable’ amorphous material, and lastly this 
thesis chapter describes the critical need to predict the crystallization mode of failure, for a 
potential compound, based upon the physicochemical descriptors of that compound. 
 
1. Utility of amorphous dispersions in the drug discovery space: 
 
Current industry trends seem to favor molecules which, without the use of technologies to 
enhance exposure, demonstrate poor oral bioavailability1,2.  Reasons for this include increased 
molecular weight, increased lipophilicity and a decrease in the solubility of many candidate 
molecules relative to drug prepared from 1980 to 20001,2.  As a result, amorphous solid 
dispersions have increased in utility in recent years as a tool to enhance oral bioavailability in 
both a clinical and preclinical setting3-10.   
The ways in which amorphous dispersions enhance exposure are four-fold.  First, in the 
amorphous state, the energy barrier to dissolve is decreased relative to the crystalline state, as no 
crystal lattice energy is present11.  Typically this results in an enhanced apparent kinetic 
solubility and can lead to faster dissolution12-15 and super saturation16-19.  Second, the amorphous 
dispersion may dissolve in such a way so as to form colloidal species in solution, which reduces 
the drug particle size and increases the surface area, thus improving the dissolution rate16,18.  
Third, typical amorphous dispersion polymers tend to have some hydrophilic character, 
depending upon the polymer selected, and can facilitate dissolution through increased wetting12-
15.  Lastly, the amorphous dispersion polymer can act as a precipitation and crystallization 
inhibitor thus sustaining supersaturation12,14,17,18. 
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Several key differences exist between the formulation presentation for a 
commercial/clinical (human) preparation and a preclinical (animal) study.  Typically, the 
primary difference between these two presentations is the need to prepare suspensions for 
preclinical studies, whereas solid oral dosage forms, such as a tablet, are frequently used for 
clinical studies and as the preferred commercial dosage form.  Nonetheless preclinical animal 
studies are an integral and important foundation for developing effacious and safe drugs. From 
this perspective, this thesis explores how physicochemical and structural properties of a model 
compound can be used to predict the potential for crystallization from a model system.  These 
empirical structure property relationships, which can be rationalized through thermondynamic 
first principals, are of utmost importance in a drug discovery setting, where limitations in drug 
supply and time/cost of manufacture in the drug discovery space make it desirable to predict the 
likelihood of obtaining a physically stable suspension prior to synthesis, scale-up and processing 
of a candidate compound2. 
A better understanding of the empirical structure property relationships observed in 
suspension crystallization studies can be obtained by considering the potential modes of failure 
for a suspension of amorphous spray dried dispersions.  It can be hypothesized that two primary 
modes of failure could include (1) dissolution of the model compound out into the suspending 
vehicle followed by crystallization in the suspending vehicle, or (2) permeation of the water into 
the amorphous solid dispersions followed by plastization/anti-solvation, which can lead to 
elevated drug mobility and an enhanced nucleation rate20-26.  
When considering failure mode 1, one must first consider whether the suspended material 
exhibits properties of a glass or a super cooled liquid, where it is hypothesized that the drug can 
more readily partition out of a material in a supercooled liquid state rather than a glass state.  In 
addition the lipophilicity of the drug is important as it represents a potential to partition into a 
water phase, and may affect the rate of crystallization from this failure mode.  Once in the bulk 
suspending media, the supersaturation and solubility of the drug in the suspending media needs 
to be considered as it represents a thermodynamic driving force for crystallization27-34.  Lastly 
the rate of nucleation in solution will be dependent upon structural (such as molecular weight 
and number of rotatable bonds) and thermodynamic (melting temperature, enthalpy and entropy 
of fusion) features of the model molecule29,30,31,33.  Each of these parameters are key components 
to classical nucleation theory, which will be discussed in more detail later in this chapter. 
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When considering failure mode 2, properties such as the glass transition temperature, or 
the glass transition temperature in the presence of moisture, may be critical in understanding the 
crystallization tendency of the model amorphous dispersion20-22,24-26.  These factors will be 
impacted by the glass transition temperature of the drug, the glass transition temperature of the 
amorphous dispersion, and the hygroscopicity of the amorphous dispersion, as water will serve 
as a plasticizer.  In addition, it is hypothesized, for amorphous dispersions in the super cooled 
liquid state, where molecular mobility is elevated, the rate of nucleation in the solid state will 
have increased sensitivity to structural (such as molecular weight and number of rotatable bonds) 
and thermodynamic (melting temperature, enthalpy and entropy of fusion) features of the model 
molecule. 
Certain properties, which are predictive of the driving force, or ease of undergoing 
nucleation, are equally important to each model.  Regardless of the failure mode, amorphous 
dispersions in the glassy state should be more stable than amorphous dispersions in the super 
cooled liquid state due to decreased molecular mobility.  In addition other properties that affect 
nucleation rates, such as molecular weight, number of rotatable bonds, melting termperature and 
other thermodynamic parameters play a critical role in each failure mode. 
 
2. Key differences between amorphous versus crystalline materials: 
 
The primary difference between a crystalline and amorphous material is the existence of 
long range lattice order11.  Crystalline materials are arranged in a lattice consisting of a repeating 
orientation/pattern in three dimensions.  These materials possess crystalline lattice energy and 
undergo a melting event (solid-liquid phase transformation) at a defined melting temperature.   In 
contrast, amorphous materials do not possess long range order.  These materials exist in a meta-
stable state in which the material possesses a higher Gibbs free energy relative to the crystalline 
state11. 
Differentiation of crystalline and amorphous materials can be made using several solid 
state characterization techniques including: differential scanning calorimetry (measuring the 
presence or absence of a melting temperature and glass transition temperature), powder x-ray 
diffraction (using x-rays to look for diffraction peaks) and polarized light microscopy (observing 
birefringence under cross polarized light)35-39. 
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Amorphous materials, having a higher Gibbs free energy than crystalline materials, 
contain a thermodynamic driving force to spontaneously crystallize11,40,41 and reduce the Gibbs 
free energy of the system. This presents an inherent physical stability risk.  For this reason 
amorphous drugs are generally prepared as amorphous dispersions within a polymer matrix.  In 
these amorphous dispersions the polymer plays a key role in the stabilization of the amorphous 
state42,43.  The polymer helps stabilize a drug, and prevent crystallization by raising the glass 
transition temperature.  This decreases the molecular mobility of the drug in the polymer 
dispersion.  The polymer also acts as nucleation inhibitor and slows growth of already formed 
crystalline material42,43. The polymer may also impart a reduction in the chemical potential of the 
drug to crystallize (reduce the thermodynamic driving force for crystallization)42,43.  Additional 
details on the polymer selection criteria for this thesis appear in Chapter 2. 
Achieving an adequate dissolution profile and a high solubility in the gastrointestinal 
milieu are key steps in enhancing oral exposure as many drugs have dissolution rate limited oral 
exposure44. The mechanism by which amorphous solid dispersions improve oral bioavailability 
has been discussed in the literature, with most discussion centering around the Noyes-Whitney 
equation (equation 1), where D is the diffusivity through the boundary layer, l is the boundary 
layer.  Reduction in the surface area (A) or a increase in the kinetic/apparent solubility over the 
thermodynamic solubility (CS) result in a faster dissolution rate and therefore elevated absorption 
in vivo6,45-47.   
Dissolution Rate = )( CC
l
DA
S −       (1) 
For amorphous materials CS is the apparent amorphous solubility, which is elevated 
relative to the thermodynamic solubility, and provides a faster dissolution driving force and an 
elevated solubility for compounds with dissolution rate limited absorption.  In addition to 
dissolution rate, an elevation CS can help improve exposure for solubility limited compounds
7-10, 
which will be described in more detail.  The elevation of the apparent amorphous solubility limit, 
relative to the crystalline equilibrium solubility, is described at length in the literature11,48-51.  A 
first calculation was proposed by Hancock and Parks11 as shown in (2) where σamorphous and 
σcrystalline are the solubility values for the amorphous and crystalline material, and ΔGa-c is Gibbs 
free energy difference between the amorphous and crystalline materials.  An approximation for 
ΔGa-c can be provided by the Hoffman equation
41 (3), where ΔHf is the enthalpy of fusion, ΔT is 
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the difference between the melting temperature and room temperature, and Tm is the melting 
temperature. 
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A more sophisticated calculation of the amorphous solubility limit has been proposed by 
Murande and Pikal48-51.  This equation employs an additional correction factor (4) based upon 
the Gibbs-Duhem equation48.  The Gibb-Duhem correction accounts for the free energy 
difference between the crystalline and hydrated amorphous state.  Equation 4 is given for an 
unionized molecule. 
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 From these thermodynamic and rate equations, and the literature referenced, it is clear 
that an amorphous dispersion can improve both the dissolution rate and apparent solubility of a 
model molecule.  If one could accurately measure the solubility difference between the 
amorphous and crystalline forms experimentally, the thermodynamic driving force of 
crystallization could be obtained.  Correlating this value with the physical stability of 
suspensions of amorphous materials could be useful for developing a predictive physical stability 
model, however measuring this amorphous/crystalline solubility ratio has proven difficult to do 
experimentally due to the driving force to crystallize11,49,50.  Nonetheless, these equations 
demonstrate a correlation between the driving force crystallization and properties such as melting 
temperature, and other thermodynamic properties, and thus these properties could play a key role 
in building a predictive model for physical stability of suspensions of amorphous dispersions.  
 
3. Preparation of amorphous materials via spray drying: 
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While amorphous solid dispersions have seen increased usage as a clinical formulation 
strategy, it is only recently that advances in technology have afforded utility of this approach in 
the preclinical space52.  This has been primarily due to challenges in making amorphous solid 
dispersions robustly at the milligram scale given the short development time and low material 
availability, which is necessary to support drug discovery programs.  Numerous ways exist to 
prepare amorphous solid dispersions including spray drying, hot melt extrusion, spray 
congealing, milling and co-precipitation7,9,10.  Spray drying has some unique advantages in the 
drug discovery space53,54 and platform conditions can be utilized to produce spray dried 
dispersions with a relatively short development time53,54.  Spray drying is a scalable process 
which can be used to produce material at the milligram to kilogram scale, although numerous 
considerations and challenges need to be taken into account when scaling the spray drying 
process53,54.  
In the drug discovery space, where formulations are typically dosed as suspensions to 
rodent and non-rodent species for pharmacology and toxicology studies, spray drying allows for 
some level of particle design and control (i.e., control of particle size and morphology).  In 
addition the rapid drying times associated with spray drying are advantageous for preparing a 
uniform amorphous dispersion53,54. Thus, a preclinical formulation scientist can design particle 
attributes to provide good suspension characteristics.  These attributes make spray drying an 
ideal unit operation for producing amorphous solid dispersions in the drug discovery space.  The 
process of spray drying appears in Figure 2. 
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Figure 2. Diagram of spray drying unit operation. 
 
In the spray drying process, an amorphous dispersion is prepared by first dissolving a 
drug and polymer in a volatile organic solvent.  This mixture is then sprayed through an 
atomizing nozzle into a stream of hot drying gas.  The solvent is rapidly evaporated leaving a 
powder containing the drug and polymer in an amorphous dispersion.  The goal of this process is 
to dry the material at a sufficient rate that crystallization is unable to occur and that the material 
is a homogenous (single phase) amorphous dispersion53,54. Concerns do exist that the material 
may be heterogeneous based upon the drying kinetics, or that residual solvent may be contained 
within the spray dried particle and require secondary drying.   While platform operating 
conditions are generally employed in the drug discovery space, downstream activities will 
require significant process definition to optimize operating conditions.  Failure to adequately 
prepare a homogenous amorphous dispersion, prior to testing in a suspension physical stability 
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model, could result in an erroneous rapid crystallization rate (either by failure mode 1 or failure 
mode 2).  For this reason each material is characterized thoroughly before physical stability 
studies are conducted. 
In a preclinical setting, the spray dried powder can be dispersed in a carrier vehicle and 
dosed as a suspension.  Numerous parameters are critical to the spray drying process including, 
selection of the processing equipment, inlet and outlet temperatures, selection of the solvent and 
carrier polymer, spray rate and atomization pressure to name a few.  Details behind the selection 
of these parameters appear in Chapter 2 of this thesis. 
 
4. Possible modes of failure for suspensions of spray dried dispersions: 
 
A suspension of a spray dried amorphous dispersion can undergo several modes of 
formulation failure.  Three hypothesized modes of failure include crystallization, poor 
flow/suspension properties and chemical degradation. Amongst these three modes of failure, 
crystallization is a large concern due to the meta-stable nature of the amorphous dispersion, and 
is the sole focus of this thesis.  Within the crystallization mode of failure, there are two primary 
modes of failure as mentioned previously, (1) dissolution of drug into the suspending vehicle 
followed by crystallization or (2) crystallization of the drug within the suspended amorphous 
dispersion particle.   
Numerous papers exist focusing on attempts to predict the shelf-life and performance of 
amorphous solid dispersions35,36,39,40,43.  These papers are focused on the preparation of clinical 
solid oral dosage formulations rather than suspensions. From this literature, it has been well 
established that the physical stability of an amorphous solid dispersion can be enhanced by (1) 
increasing the polymer to drug ratio, (2) decreasing the storage temperature and (3) protecting 
the amorphous dispersion from moisture20-26.  Unfortunately, in the preclinical space, where 
suspensions of spray dried dispersions are utilized, there is limited ability to control any of these 
three factors.  First, target doses, especially for high dose safety studies, may necessitate a high 
drug loading in the amorphous solid dispersion.  This can limit the maximum achievable dose 
which can lead to a gumming, gelling or caking of the material at high dose (a commonly 
encountered mode of failure).  Second, suspensions of amorphous solid dispersions encounter 
100% relative humidity via direct contact with the aqueous environment of the suspending 
9 
 
vehicle.  As previously mentioned this can promote crystallization, by increasing the 
thermodynamic driving force for crystallization, through two modes of failure, as it allow for 
both a plasticizing effect anti-solvation effect on the amorphous dispersion particles.  This can 
lower the glass transition temperature from a glassy state to a super cooled liquid state as water 
penetrates the solid particles.  This can also promote crystallization with the solid state material 
(failure mode 2) or can solubilize drug into the bulk suspending media, where the drug is free to 
crystallize in the absence of the undissolved polymer to inhibit crystallization (failure mode 1). 
Upon examining crystallization of suspensions of spray dried dispersions, it is critical to 
understand the difference between nucleation and growth of crystals29,30.  Nucleation is the 
spontaneous formation of a crystalline material.  Growth involves monitoring the increasing size 
of the crystalline material.  This thesis focuses on detecting the onset of crystallization 
(nucleation) rather than on monitoring the growth of already formed crystalline material, as the 
formulation would need to be dosed prior to observable crystalline content (prior to 
failure/nucleation).  The inability of a preclinical formulation scientist to accurately assess the 
impact of low levels of crystallization on bioperformance/oral absorption, and the inability to 
accurately quantify the crystallized content in suspension, precludes the use of partially 
crystallized suspensions reliably in the drug discovery setting. 
The nucleation process can be described by classical nucleation theory (CNT).  CNT 
describes the precipitation of particles from supersaturated solutions.  In CNT, nucleation centers 
evolve until a critical size of repeating molecules is reached29,30.  Equation 5 describes the most 
basic view of classical nucleation theory where K0 is a pre-exponential factor, ΔGcrit is driving 
force for nucleation, and kB is the Boltzman constant.  Of importance to this thesis are parameters 
which can affect ΔGcrit and K0. Factors affecting ΔGcrit include thermodynamic factors, such as 
melting temperature, and entropy and enthalpy of fusion.  ΔGcrit can also be related to the 
supersaturation of the drug, either in the suspending media (failure mode 1) or in the amorphous 
solid dispersion matrix (failure mode 2)29-34. K0 can be related to structural features associated 
with the ease of molecular stacking into a crystal lattice.  These parameters could be affected by 
molecular descriptors such as molecular weight, number of rotatable bonds or surface 
tension29,30. 





 Δ−=
Tk
G
KRateNucleation
B
critexp0       (5) 
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5. Predicting crystallization of suspensions of amorphous dispersions: 
 
In the drug discovery/preclinical setting it is clear that suspensions of amorphous 
dispersions can provide a useful tool for exposure enhancement of compounds with low 
solubility3-10.  This potential exposure enhancement may come with a risk of formulation failure, 
of which crystallization is the critical concern.  However, the current literature lacks tools to 
predict which compounds are likely to encounter failure due to crystallization when formulated 
as suspensions of amorphous dispersions.  Literature does exist to predict crystallization of 
amorphous materials in the solid state in a dry environment35,39,42,43, in a humid environment20-26 
and predict crystallization from solution38-34.  However, none of the current literature adequately 
predicts what will happen to suspensions of spray dried dispersions.  Limitations in drug supply 
and time/cost of manufacture in the drug discovery space make it desirable to predict the 
likelihood of obtaining a stable (free from detectable crystallization) suspension prior to 
synthesis, scale-up and processing of a candidate compound. 
In order to experimentally determine which properties impact the potential of the model 
system to show signs of crystallization, 24 poorly water soluble model compounds were selected 
with a wide range of physicochemical properties (details appear in Chapter 2).  These poor 
solubility model compounds were selected in order to represent random model compounds which 
could appear in a drug discovery pipeline.  Additional details regarding selection criteria appear 
in Chapter 2. 
The following structural descriptors were assessed for each model compound: molecular 
weight, number of rotatable bonds, number of hydrogen bond donors and number of hydrogen-
bond acceptors.  Each of these parameters helps to characterize the model compounds in terms of 
size, shape and propensity to participate in hydrogen bonding.  In addition, several of these 
properties can be explored as a ratio, for instance normalizing by molecular weight.  
The following thermal properties were assessed for each model compound: melting 
temperature, enthalpy of fusion, entropy of fusion, Gibbs free energy, as well as the glass 
transition temperature of the drug substance and dry amorphous dispersion.   
The following hydrophilicity properties were assessed for each model compound: water 
solubility, water solubility calculated from the general water solubility equation, platform vehicle 
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solubility, hygroscopicity (as defined by moisture weight gain at 90% RH) and the glass 
transition temperature of the amorphous dispersion at 100% RH. Interactions with water are of 
utmost importance to amorphous suspension formulations since the amorphous spray dried 
dispersions encounters 100% humidity.  Both failure mode 1 and failure mode 2 describe 
interactions with water either as a solvent/anti-solvent, a plasticizer or a bulk solution in which 
the drug can dissolve into. 
In addition to assessing properties in a uni-variate fashion, a multi-variate model was 
developed in this thesis which incorporates numerous parameters.  Preclinical scientists will be 
able to utilize the output from this thesis to predict which compounds will have adequate 
crystallization stability in a platform suspension.  As mentioned previously, this will save 
resource expenditure in the drug discovery space with time and drug substance supply are 
limited. 
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Chapter 2: Amorphous Dispersion Suspension Crystallization Studies 
 
Chapter 2 outlines the selection of the model systems used in this thesis.  The chapter 
illustrates how compounds were selected based upon a need for a diverse set of physicochemical 
properties. The drivers for selecting a 33.3% drug load HPMCAS-L amorphous solid dispersion 
and the model suspending vehicle (0.5% methocellulose + 0.25% Sodium Lauryl Sulfate + 5 mM 
HCl) are also described in detail. In addition to the selection of the model systems, important 
details around the spray drying process and characterization of material are discussed.  Lastly, 
the chapter outlines how crystallization studies were conducted and presents the composite data 
from those studies. 
 
1. Selection of the model polymer/dispersion system: 
  
Hydroxypropylmethyl cellulose acetate succinate L grade (HPMCAS-L) was selected as 
a model dispersion polymer.  This polymer was selected for several reasons including (1) 
precedent in the literature55,56, (2) an elevated glass transition temperature which helps stabilize 
the amorphous dispersion from crystallization55,56, (3) acidic/enteric nature of the succinate 
moiety of the polymer (useful from a solubilization control versus pH standpoint) and (4) 
hydrophilic/surface active properties at neutral pH (useful from an in vivo anti-nucleation 
standpoint)55-57.  The pH-dependent nature of this polymer is of particular importance to the 
design of the suspensions. The pH-dependent solubility of the polymer allows for the preparation 
of a stable suspension below pH 5.5, while still allowing for release of the drug at 
neutral/intestinal pH55-57.  In addition upon release of the drug at pH 5.5, the polymer acts as an 
anti-nucleation agent55-57. 
 A platform drug loading of 33.3% w/w drug/polymer was selected for the model 
amorphous dispersions.  This drug loading was selected based upon literature precedence as a 
model drug loading14,55.  In addition, this drug loading can be rationalized in the following way.  
For drug loadings below 20%, the maximum dose-able concentration decreases since the 
majority of each solid particle is comprised of polymer, this is important since several drug 
discovery studies (e.g., pharmacology and toxicology) require high doses.  For drug loadings 
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above 50%, there is an inherent crystallization stability risk in both the solid state and the 
suspended state55. 
 
2. Selection of the model compounds: 
 
 The following 24 model compounds were selected for this thesis: nevirapine, piroxicam, 
griseofulvin, chlorpropamide, tolazamide, indoprofen, fenofibrate, carbamazepine, telmisartan, 
aprepitant, felodipine, omperizole, bifonazole, telaprevir, ketonconazole, miconazole, 
itraconazole, indomethacin, clofoctol, ritonavir, efavirenz, clotrimazole, torcetrapib, and 
celecoxib.  These molecules were selected, after careful consideration, based upon the following 
criteria.  First, a large number of these molecules have been prepared as amorphous dispersions 
in the pharmaceutical literature, and therefore historical data can be leveraged and these 
compounds have precedence as representing poorly water soluble pharmaceutical molecules.  
Second, the physical chemical properties of these molecules cover a large range of 
physicochemical space.  Key properties include molecular weight (200 to 800 dalton), number of 
rotatable bonds (0 to 10), ionization state (acidic, basic, neutral and zwitterionic) glass transition 
temperatures (-20 to 100 °C), Log P (0 to 9) and melting temperature (100 to 300 °C).  By 
covering a large range of the possible physicochemical properties in a pharmaceutical 
development pipeline, this data set helps us identify which parameter, or parameters, are most 
predictive of the amorphous suspension physical stability of amorphous dispersions of future 
molecules.  In addition these properties bracket the range of molecules which are typically 
considered drug like1,2 with all molecules reaching phase IIB in clinical trials or the market.  
 
3. Selection of a model/platform suspending vehicle: 
 
 A model suspending vehicle for a suspension of amorphous spray dried material, 
containing a pH-dependent polymer, generally contains three key components.  The first 
component is a pH modifier, in this case 5 mM HCl was selected.  Other pharmaceutically 
acceptable potential options could include buffering agents such as citrate, tartrate, acetate or 
other weak acids.  HCl was selected, due to a simple ionic structure, which is less likely to act as 
an anti-nucleation agent, and confound the measurements.  This component acidifies the pH and 
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prevents release of the compound from the pH-dependent HPMCAS polymer.  The second 
component of a model suspending vehicle is a viscosity enhancer.  This component is added to 
prevent rapid settling of the suspension.  In this case 0.5% methocellulose was selected as it is a 
common suspending agent.  Other pharmaceutically acceptable potential viscosity enhancing 
agents could include other cellulosic polymers or other polymers such as povidone or co-
povidone.  The third component is a surfactant which will help improve the wetting of 
HPMCAS.  In this case 0.25% SLS was selected as a model surfactant with the surfactant 
amount just above the critical micelle concentration for SLS58.  Other pharmaceutically 
acceptable potential surfactants could include polysorbates and poloxamers.  SLS was selected, 
due to a simple non-polymeric structure, which is less likely to act like an anti-nucleation agent, 
and confound the measurements. 
 
4. Spray Drying Processing Parameters: 
  
a.) Materials:  
 
Analytical HPLC Grade acetone, methanol and tetrahydrofuran (Sigma-Aldrich; 
tetrahydrofuran inhibited with butylated hydroxytoluene to prevent peroxide formation), 
HPMCAS-LF (Shin-Etsu), griseofulvin (Sigma), indoprofen (Sigma), Chloropropamide (TCI-
GR), neviripine (Ava Chem Scientific), celecoxib (Matrix Scientific), tolazamide (Sigma), 
bifonazole (MP Biomedicals), itraconazole (Spectrum), miconazole (Spectrum), indomethacin 
(MP Biomedicals), piroxicam (MP Biomedicals), clotrimazole (Sigma), ketoconazole 
(Spectrum), clofoctol (Sigma), telaprevir (Merck), efavirenz (Merck), ritonavir (Merck), 
aprepitant (Merck), felodipine (Ontario), torcetrapib (Merck), telmisartan (Astatech), 
carbamazepine (Acros), fenofibrate (Sigma), and omerprazole (Spectrum).  All compounds 
obtained were greater than 97% purity and used as received. 
 
b.) Preparation of the spray dried dispersions: 
 
The drug substance and HPMCAS were dissolved in acetone, methanol or 
tetrahydrofuran, with preference given to acetone and methanol to avoid any safety risks 
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associated with spray drying from tetrahydrofuran, which is a solvent which can form peroxides 
upon prolonged exposure to oxygen.  The mixture was stirred on a magnetic stir plate or 
submersed into a Branson Ultra-Sonicator until all components had dissolved.  Materials were 
spray dried using a ProCepT Microspray Dryer with a bi-fluid nozzle.  Unless there were 
solubility limitations, the solid loading was fixed at 40 mg of solid per milliliter of solvent, 
although a few compounds, such as itraconazole and telmisartan, needed further dilution to fully 
solubilize.  Other key parameters include nozzle size (0.6 or 0.8 mm), spray rate (5-8 mL/min), 
outlet drying temperature (5-10 °C below solvent boiling point) and atomization air flow (3-6 
L/min).  In all cases the spray dried dispersion was stored overnight in a vacuum oven (30 in Hg 
vaccum) at room temperature to evaporate residual moisture and solvents.  Additional heating 
was avoided due to concerns that additional heat could promote crystallization. 
 
5. Characterization of spray dried amorphous dispersion: 
 
 Spray dried materials were characterized using powder x-ray diffraction (PXRD) to 
assess crystallinity, modulated differential calorimetry (mDSC) to assess crystallinity and 
measure the glass transition temperature of the spray dried material, thermal gravimetric analysis 
(TGA) to assess residual solvent/moisture, polarized light microscopy (PLM) to evaluate particle 
size and crystallinity, high performance liquid chromatography (HPLC) to evaluate purity and 
potency and laser light scattering (LLS) to assess particle size and distribution. 
PXRD measurements were taken with a Phillips XPERT instrument.  Samples were 
scanned continuously from 0-40 2θ over 1 hour using a tension of 45 kV and a current of 40 mA.  
Key optics parameters include: a PW3373/10 CuLFF DK164254 tube, a 240 mm beam radius, a 
6° take-off angle and a1.54 Å wavelength.  A sample PXRD scan for an Itraconazole amorphous 
dispersion is shown in Figure 3.  The full characterization data set for each of the 24 model 
compounds appears in Appendix 1. 
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Figure 3. PXRD scan for Itraconazole 33.3% Drug Loading in HPMCAS. Note the lack of 
crystalline reflections and the presence of an amorphous halo. 
 
Modulated DSC measurements were taken to assess phase uniformity and the glass 
transition temperature of each amorphous material.  Approximately 3-5 mg of sample was loaded 
into a hermetically sealed pan with a pin hole in the top.  The sample was loaded onto a TA 
Instruments Q2000 DSC and was heated from 35 to 170 °C with a modulation amplitude of 
0.5 °C, a modulation period of 60 sec, and a ramp rate of 2 °C/min.  A sample mDSC scan is 
shown for an Itraconazole amorphous solid dispersion in Figure 4.  The full characterization data 
set for each of the 24 model compounds appears in Appendix 1. 
 
Figure 4. A modulated DSC trace for 33.3% Itraconazole/66.7% HPMCAS w/w % spray dried 
dispersion.  Note the existence of a single Tg suggesting a single amorphous phase.  Note that 
the Tg of HPMCAS-L is 118 to 120 °C55. 
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Polarized light microscopy samples were analyzed using a Nikon Eclipse ME600 under a 
20x objective utilizing cross-polarizering filters and image capture capability to look for particle 
size, shape, morphology and birefringence. A PLM image for an Itraconazole amorphous 
dispersion is shown in Figure 5.  The full characterization data set for each of the 24 model 
compounds appears in Appendix 1. 
 
 
Figure 5. Polarized microscopy image of 33.3% Itraconazole/66.7% HPMCAS w/w % spray 
dried dispersion. Note spherical/raison-like morphology and lack of birefringence under cross 
polarized light. 
 
TGA was conducted for select amorphous dispersions to attempt to gain a typical residual 
solvents and moisture range.  Samples were loaded onto a TA Instruments Q5000 and heated 
from room temperature to 170 °C at 20 °C/min. The full characterization data set appears in 
Appendix 1. 
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Figure 6. TGA data for spray dried amorphous dispersions (from top to bottom) of Piroxicam, 
Fenofibrate, Miconazole, Clotrimazole, Tolazamide, Indoprofen and Clofoctol in HPMCAS-LF 
at 33.3% DL. 
 
HPLC was conducted for numerous amorphous dispersions to verify correct drug 
loading.  Samples were diluted in 75:25 MeCN:water approximately to 0.1-0.2 mg/mL.  Samples 
were then analyzed on a 10 minute linear gradient from 95:5 A:B to 10:90 A:B where A and B 
are 0.1% H3PO4 and MeCN respectively.  Samples were analyzed verses a reference standard of 
the compound dissolved in 75:25 MeCN:water. HPLC analysis were conducted at 210 nm and 
the column compartment contained a Supelco Ascentis Express C18 (10cm x 4.6mm, 2.7 μm) 
column heated to 40 °C. From these studies one could conclude that an accurate potency for the 
amorphous dispersions had been obtained.  Additional data appears in Appendix 1. 
LLS studies were conducted on select samples to measure the representative particle size 
and distributions for spray dried amorphous dispersions prepared on the ProCepT Micro-Spray 
Dryer. Particle size distribution was measured with a HELOS/KF-Magic laser diffraction particle 
size analyzer by Sympatec.  The instrument was equipped with a RODOS dry disperser and a 
VIBRI feeder. R1 lens with a measure range of 0.13-32.08 μm was selected for measurements.  
The measurement was performed under the dry dispersion mode with a dispersing pressure at 2.5 
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bars.  Typical results from an Itraconazole amorphous dispersion are shown in Figure 7.  
Additional data is available in Appendix 1.  This method was selected because the particle size 
for the spray dried dispersion was appropriate for the lens range.  In addition the dispersion 
pressure was selected so as to prevent destruction of primary particles. 
 
 
 
Figure 7. Laser light scattering particle size data for spray dried 33.3% Itraconazole/66.7% 
HPMCAS w/w %.  
 
 The particle size, of spray dried amorphous dispersions, can be sensitive to spray drying 
parameters and to the scale of the spray drying operation, thus it is important to make these 
measurements to ensure the material prepared for suspension physical stability studies is within a 
consistent range. 
 
6. Suspension physical stability (onset of crystallization) studies: 
 
Suspensions of the amorphous spray dried dispersions were prepared by suspending 120 
mg of material in 2 mL of platform vehicle (i.e., 60 mg/mL amorphous dispersion; 20 mg/mL 
drug; 100 mg/kg drug when dosed at 5 mL/kg).  This model dose/concentration would be a 
pharmaceutically relevant dose for either a toxicology or pharmacology animal study.  The exact 
onset of crystallization is not possible to determine due to instrument sensitivity, but in the 
present work onset of crystallization was bracketed by determining a time point where 
crystallization was not observed and a time point where crystallization was confirmed. These 
experiments used two orthogonal techniques, PXRD and PLM.   
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Figure 8 shows an example of the experimental data for Bifonazole (See Appendix 2 for 
the full data set).  The physical stability data from the 24 model amorphous dispersions is 
compiled in Figure 9.   Note that within Figure 9 model amorphous dispersions have been color 
coded.  The amorphous dispersions which showed signs of crystallization within 20 minutes, 
have been color coded red, as it would not be possible to dose these amorphous dispersions 
without risk of crystallization.  Three hours was selected as a reasonable time for preparation and 
dosing of numerous animals on a pharmacology or toxicology study.  Activities to support a 
study would include formulation preparation, drawing the formulation into syringes, and 
administering the formulation to each sample subject.  It is acknowledged that a faster or slower 
time may occur depending upon the study design and number of groups involved. The 
amorphous dispersions which did not show signs of crystallization within 3 hours were color 
coded green, as these amorphous dispersions would have a physical stability window which 
would be sufficient for dosing in a preclinical setting.  Amorphous dispersions which had more 
than 20 minutes of physical stability, but less than 3 hours of physical stability, were color coded 
orange.  Also, note that due to the delineation of the data into 3 groups, selection of 2 hours 
versus 4 hours would not change the categorization of molecules. 
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Figure 8. Comparison of Bifonazole prepared as 33.3% active spray dried amorphous solid 
dispersions in HPMCAS-LF and suspended in 0.5% methocellulose + 0.25% SLS + 5 mM HCl 
at 4 and 8 hour time points by PXRD and PLM. 
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Figure 9.  Onset of crystallization (in hours) summary of 24 model compounds prepared as 
33.3% active spray dried amorphous solid dispersions in HPMCAS-LF and suspended in 0.5% 
methocellulose + 0.25% SLS + 5 mM HCl.  Note the red color coding denoting a crystallization 
time of less than 20 minutes, the orange color coding for crystallization time between 20 minutes 
and 3 hours and the green color coding denoting a crystallization time of greater than 3 hours. 
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Chapter 3: Uni-variate Analysis of Molecular Descriptors: 
 
 Chapter 3 focuses on comparing the previously generated amorphous suspension 
crystallization data with the tabulated descriptors (See Tables 1, 2 and3) of each of the 24 model 
compounds. Initially comparisons are made between the physical stability data and structural 
descriptors for each compound.  This is followed by a comparison of the physical stability data 
with thermal descriptors for each model compound. Lastly, the physical stability data is 
compared to hydrophilicity parameters.  From these comparisons it is clear that one descriptor 
alone is not sufficiently predictive of the tendency of these compounds to crystallize as 
amorphous suspensions, and additional multi-variate analysis will be required in Chapter 4. 
 
Structural Descriptors: 
The molecular weight, number of rotatable bonds, and number of hydrogen bond 
donating and accepting groups for each molecule were determined from the structure of each 
model molecule. Table 1 contains the structural descriptors of the 24 model compounds.  
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Table 1. Structural descriptors of the 24 model compounds. 
Model Compound 
Molecular 
Weight 
Number of 
Rotatable Bonds 
Number of 
H-Donors 
Number of H-
Acceptors 
Nevirapine 267 1 1 3 
Griseofulvin 353 3 0 6 
Indoprofen 281 3 1 4 
Chlorpropamide 277 3 2 3 
Tolazamide 311 3 2 4 
Piroxicam 331 5 2 6 
Bifonazole 310 4 0 1 
Clofoctol 365 5 1 1 
Celecoxib 381 3 1 1 
Itraconazole 706 11 0 7 
Miconazole 416 6 0 2 
Ketoconazole 531 7 0 5 
Clotrimazole 345 4 0 1 
Indomethacin 358 4 1 4 
Telaprevir 680 14 4 8 
Efavirenz 316 3 1 2 
Ritonavir 721 18 4 6 
Aprepitant 534 8 2 5 
Felodipine 384 6 1 3 
Torcetrapib 600 10 0 6 
Telmisartan 515 7 1 4 
Carbamazepine 236 0 1 1 
Fenofibrate 361 7 0 3 
Omeprazole 345 5 1 5 
 
 
Thermal Descriptors: 
The melting temperature, enthalpy of fusion and entropy of fusion of each compound was 
determined via either a literature search (See Appendix 3 for reference data) or via DSC analysis 
(Approximately 3-5 mg of sample was loaded into a hermetically sealed pan with a pin hole in 
the top.  The sample was analyzed with a TA Instruments Q2000 DSC and was heated from 
room temperature to 300 °C with a ramp rate of 10 °C/min).  The Gibbs free energy of each 
compound was determined using the Hoffman equation (equation 3). 
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The glass transition temperature of each drug substance and spray dried dispersion was 
determined via either a literature search (See Appendix 3 for reference data) or via DSC analysis 
(Approximately 3-5 mg of sample was filled into a hermetically sealed pan with a pin hole in the 
top.  The sample was analyzed with a TA Instruments Q2000 DSC and was heated from 35 to 
170 °C with a modulation amplitude of 0.5 °C, a modulation interval of 60 sec, and a ramp rate 
of 2 °C/min). 
The crystallization classification for cyclic DSC experiments was determined by either a 
literature search (See Appendix 3 for reference data), or by cyclic DSC (Approximately 3-5 mg 
of sample was weighed into a hermetically sealed pan with a pin hole in the top.  The sample was 
analyzed with a TA Instruments Q2000 DSC and was heated from room temperature to 5 °C 
above the melting temperature with a ramp rate of 10 °C/min.  The sample was then held 
isothermal for 2 minutes.  The sample was then cooled to 25 °C at 10 °C/min.  The sample was 
then heated to the melting temperature at 10 °C/min).  A drawback with this method is the 
possibility of chemical degradation during the analysis.  Due to the sample size, 24 model 
compounds, detailed chemical stability analysis was not conducted. 
 
Table 2 contains the thermal descriptors of the 24 model compounds. 
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Table 2. Thermal descriptors of the 24 model compounds. 
Model 
Compound 
Melting 
Temp. 
(deg C) 
Enthalpy 
Fusion 
(kJ/mol) 
Entropy 
Fusion 
(kJ/K*mol) 
Hoffman 
Delta G 
(kJ/mol) 
Tg, 
Drug 
(deg C) 
Tm/Tg, 
Drug 
Tg,dry 
Dispersion 
(deg C) 
Cyclic 
DSC 
Class 
Nevirapine 246 39.5 0.076 10.6 76 1.49 80 1 
Griseofulvin 218 39.1 0.079 10.4 89 1.36 88 1 
Indoprofen 212 36.0 0.074 9.54 50 1.5 70 1 
Chlorpropamide 124 27.4 0.069 6.34 16 1.37 90 1 
Tolazamide 172 43.4 0.098 11.1 18 1.53 73 2 
Piroxicam 240 34.5 0.067 9.25 62 1.53 80 3 
Bifonazole 151 39.2 0.092 9.69 17 1.46 88 2 
Clofoctol 88 35.1 0.097 6.98 -4 1.34 89 2 
Celecoxib 163 37.4 0.086 9.44 58 1.32 72 2 
Itraconazole 168 57.6 0.129 14.6 58 1.33 89 3 
Miconazole 160 32.7 0.091 6.43 1 1.58 81 3 
Ketoconazole 150 52.9 0.125 13.1 45 1.33 95 3 
Clotrimazole 145 31.8 0.076 7.7 30 1.38 86 3 
Indomethacin 161 37.6 0.086 9.46 45 1.36 73 3 
Telaprevir 239 56.5 0.110 15.1 71 1.49 106 3 
Efavirenz 137 15.6 0.038 3.74 38 1.32 82 3 
Ritonavir 121 60.4 0.153 13.86 50 1.22 81 3 
Aprepitant 254 49.2 0.093 13.20 89 1.46 99 2 
Felodipine 145 31.0 0.074 7.57 45 1.31 77 3 
Torcetrapib 90 30.8 0.085 6.20 22.4 1.23 100 3 
Telmisartan 269 52.9 0.098 14.3 128 1.35 109 3 
Carbamazepine 190 25.5 0.055 6.65 61 1.39 69 1 
Fenofibrate 80 33.0 0.093 6.24 -19 1.39 79 3 
Omeprazole 159 26.6 0.062 6.67 45 1.36 71 3 
 
Hydrophilicity Descriptors: 
Here the term hydrophilicity descriptor is defined as descriptors which involve the 
interaction of a model compound with water.  Descriptors include aqueous solubility, Log P and 
pKa were determined via a literature search (See Appendix 3 for reference data). 
The solubility in the platform vehicle (0.5% methocellulose + 0.25% SLS + 5 mM HCl) 
was determined by stirring excess crystalline drug with the vehicle for 48 hours at 25 °C.  Given 
the number of samples required for testing, 48 hours was approximated to represent the 
equilibrium solubility (although attainment of equilibrium was not verified in the studies).  
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Samples were then filtered through 0.22 µm PTFE filters.  The filtrate was then analyzed by 
HPLC using the same method described in Chapter 2. 
The General Solubility Equation for each compound was determined by using equation 6, 
where SCrystalline is the crystalline solubility and Tm is the melting temperature
59. 
 
( ) ( ) LogPTmSLog eCrystallin −−×−= 2501.05.0      (6) 
 
Moisture sorption isotherms were taken of each model spray dried amorphous dispersion. 
Approximately 5 mg of the amorphous dispersion was loaded onto a TA Instruments Q5000 
TGA.  Samples were dried at 60 °C for 1 hour followed by a ramp up, and ramp down, in 
humidity (10 to 90 to 10% RH).  Each sample was held at a given relative humidity until there 
was less than 0.01% weight change over 5 minutes. 
The Tg,dispersion,100%RH was calculated using the equation (7).  This equation was derived 
from work done by Marsac60 and Andronis61.  The Tg,dispersion,100%RH was calculated, rather than 
measured, due to the inherent difficulty of measuring this value without a sample undergoing 
crystallization or phase transformation. 
 
Tg,dispersion,100%RH = Tg,dispersion,dry – 10 °C × extrapolated % wt. gain @ 100% RH           (7) 
 
Table 3 contains the hydrophilicity descriptors of the 24 model compounds. 
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Table 3. Hydrophilicity properties of the 24 model compounds. 
Model 
Compound Log P pKa 
Water 
Solubility 
(mg/mL) 
General 
Solubility 
Equation 
(mg/mL) 
Vehicle 
Solubility 
(mg/mL) 
% Wt. 
Gain at 
90% 
RH 
 
Tg,dispersion,100%RH 
Nevirapine 2.5 2.8 0.0007 0.016 0.443 6.2 1 
Griseofulvin 0.7 x 0.0086 2.61 0.859 5.5 15.5 
Indoprofen 2.8 5.1 - 0.019 0.031 6.7 8 
Chlorpropamide 1.8 4.3 0.157 1.42 0.215 5.6 20 
Tolazamide 1.4 3.6 0.308 1.33 0.153 5.7 5 
Piroxicam 0.6 1.8, 5.1 0.143 1.86 0.250 4.3 20 
Bifonazole 4.7 6.7 0.0025 0.0012 0.453 2.6 52 
Clofoctol 8.2 x 0.0022 0.000001 0.02 6.2 48 
Celecoxib 4.3 11.1 0.0033 0.0025 0.093 4.2 17 
Itraconazole 7.3 3.7 0.0009 0.000004 0.011 4.5 33 
Miconazole 5.1 6.7 0.0007 0.0026 0.721 3.1 42 
Ketoconazole 3.5 2.9 0.0001 0.029 1.84 5.0 25 
Clotrimazole 5.2 6.6 0.0147 0.0004 0.997 2.9 50 
Indomethacin 3.6 4.5 0.0009 0.012 0.044 5.0 11 
Telaprevir 4.0 11.9 0.0047 0.001326 - 6.4 26 
Efavirenz 4.6 12.5 0.0082 0.001777 - 4.4 31 
Ritonavir 5.6 2.8 0.0013 0.000628 - 6.1 9 
Aprepitant 4.5 9.7 0.019 0.000274 - 6.3 27 
Felodipine 3.9 5.4 0.0009 0.009646 - 4.8 17 
Torcetrapib 7.8 - - 1.47E-05 - 5.3 30 
Telmisartan 6 
3.5, 4.1, 
6.0 0.004 6.95E-06 - 4.7 57 
Carbamazepine 2.7 x 0.17 0.033336 - 4.8 5 
Fenofibrate 4.8 x 0.25 0.005099 - 4.4 24 
Omeprazole 2.4 4.0 0.357 0.212725 - 6.0 10 
 
 
Uni-variate analysis of the descriptors data set for the 24 model compounds: 
 
Initially uni-variate analysis of the data set was conducted to compare how the 
amorphous suspension crystallization data correlated with the possible descriptors.  Description 
of this analysis is broken up between the structural, thermal and hydrophilicity parameters. 
 
a.) Structural Descriptors: 
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Uni-variate analysis was attempted for the various structural descriptors including 
molecular weight, number of rotatable bonds and number of hydrogen bond donating and 
accepting groups.  The plots of these data are shown in Figures 11, 12, 13 and 14. In addition, 
Figures 15, 16 and 17 show the normalized (by molecular weight) data for number of rotatable 
bonds, hydrogen bond donor and acceptor groups. 
 
Figure 11. Molecular weight versus onset of crystallization time for 33.3% drug/66.7% 
HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM HCl. Note 
the red circle color coding denoting a crystallization time of less than 20 minutes, the orange 
triangle color coding for crystallization time between 20 minutes and 3 hours, and the green 
diamond color coding denoting a crystallization time of greater than 3 hours. 
 
When looking at molecular weight for the 24 model compounds, compounds with higher 
molecular weight values show less of a propensity to crystallize than those with lower molecular 
weight values.  For compounds with a molecular weight >400, 6 of the 8 compound crystallize 
after 3 hours, 2 of the 8 compounds crystallize between 20 minutes and 3 hours, and none of the 
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8 compounds crystallize before 20 minutes.  This parameter may be explained by the complexity 
of crystal nucleation or the slow diffusivity into the vehicle.  For instance compounds with 
elevated molecular weight may have delayed crystallization kinetics in our model system, as 
predicted by classical nucleation theory29,30 in Chapter 1, as it may take longer for the molecules 
to orient into a repeating pattern in a crystal lattice. 
 
 
Figure 12. Number of rotatable bonds versus onset of crystallization time for 33.3% drug/66.7% 
HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM HCl. Note 
the red circle color coding denoting a crystallization time of less than 20 minutes, the orange 
triangle color coding for crystallization time between 20 minutes and 3 hours, and the green 
diamond color coding denoting a crystallization time of greater than 3 hours. 
 
When looking at number of rotatable bonds, for the 24 model compounds, there is 
considerable variability in the data.  However, a trend does appear in which compounds with 
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values above 8 show less of a propensity to crystallize within 3 hours than those with values 
below 8.  Like molecular weight, this parameter may elude to the complexity of crystal 
nucleation as outlined in Chapter 1 and predicted by classical nucleation theory.  For instance 
compounds with an elevated number of rotatable bonds, have increased number of geometrical 
arrangements possible for the molecule.  This increased geometrical freedom to rotate may delay 
crystallization kinetics in our model suspension system, as it may take longer for the molecules 
to line up in the correct orientation for crystallization29,30.   
 
 
Figure 13. Number of hydrogen bond donating groups versus onset of crystallization time for 
33.3% drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS 
+ 5 mM HCl.  Note the red circle color coding denoting a crystallization time of less than 20 
minutes, the orange triangle color coding for crystallization time between 20 minutes and 3 
hours, and the green diamond color coding denoting a crystallization time of greater than 3 
hours. 
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Figure 14. Number of hydrogen bond accepting groups versus onset of crystallization time for 
33.3% drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS 
+ 5 mM HCl. Note the red circle color coding denoting a crystallization time of less than 20 
minutes, the orange triangle color coding for crystallization time between 20 minutes and 3 
hours, and the green diamond color coding denoting a crystallization time of greater than 3 
hours. 
 
Figure 13 and 14 attempt to show how the number of hydrogen bond accepting groups 
(Figure 13) and donating groups (Figure 14) correlate with the rate at which the model 
suspension system crystallizes.  The data shown in the figures suggests that the number of 
hydrogen bond accepting groups and the number of hydrogen bond donating groups plays 
minimal role in the crystallization kinetics of the model suspension system.  However, there may 
be a slight trend that compounds with >4 hydrogen bond donating groups are less likely to 
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crystallize within 3 hours in the model suspension system, unfortunately the limited sample size 
prevents a firm conclusion 
 
 The number of rotational bonds/molecular weight (Figure 15), hydrogen bond accepting 
groups/molecular weight (Figure 16) and the hydrogen bond donating groups/molecular weight 
(Figure 17) were also plotted to normalize for molecular weight. 
 
Figure 15. Number of rotatable bonds/molecular weight versus onset of crystallization time for 
33.3% drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS 
+ 5 mM HCl. Note the red circle color coding denoting a crystallization time of less than 20 
minutes, the orange triangle color coding for crystallization time between 20 minutes and 3 
hours, and the green diamond color coding denoting a crystallization time of greater than 3 
hours. 
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Figure 16. Number of hydrogen bond acceptors/molecular weight versus onset of crystallization 
time for 33.3% drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 
0.25% SLS + 5 mM HCl. Note the red circle color coding denoting a crystallization time of less 
than 20 minutes, the orange triangle color coding for crystallization time between 20 minutes and 
3 hours, and the green diamond color coding denoting a crystallization time of greater than 3 
hours. 
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Figure 17. Number of hydrogen bond donors/molecular weight versus onset of crystallization 
time for 33.3% drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 
0.25% SLS + 5 mM HCl. Note the red circle color coding denoting a crystallization time of less 
than 20 minutes, the orange triangle color coding for crystallization time between 20 minutes and 
3 hours, and the green diamond color coding denoting a crystallization time of greater than 3 
hours. 
 
Of the various structural descriptors, molecular weight is the most predictive parameter 
of physical stability.  For compounds with a molecular weight >400, 6 of the 8 compound 
crystallize after 3 hours, 2 of the 8 compounds crystallize between 20 minutes and 3 hours, and 
none of the 8 compounds crystallize before 20.   
 
b.) Thermal Descriptors: 
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Uni-variate analysis was attempted for the various thermal property descriptors including 
glass transition temperature of the model amorphous dispersion, glass transition temperature of 
the model drug substance, the melting temperature of the model drug substance, the entropy of 
fusion, enthalpy of fusion and Gibbs free energy of the model drug substance, as well as the 
crystallization tendency classification (as predicted by cyclic DSC) and the drug substance 
melting temperature/glass transition temperature ratio. The plots of these data are shown in the 
subsequent figures. 
The glass transition temperature was first evaluated.  For solid oral dosage formulations, 
it is relatively accepted in the literature that an elevated amorphous dispersion glass transition 
temperature should correlate with solid state stability35,36,39,40.  However, for suspensions of 
amorphous dispersions, there is not a strong correlation between the glass transition temperature 
of a model compound and the solid state stability of the amorphous dispersion in suspension.  
However, Figure 18 does not include an adjustment for how humidity would depress the glass 
transition temperature. 
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Figure 18. Amorphous dispersion glass transition temperature versus onset of crystallization time 
for 33.3% drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% 
SLS + 5 mM HCl. Note the red circle color coding denoting a crystallization time of less than 20 
minutes, the orange triangle color coding for crystallization time between 20 minutes and 3 
hours, and the green diamond color coding denoting a crystallization time of greater than 3 
hours. 
 
A correlation between the glass transition temperature of the drug substance and the time 
for onset of crystallization in our model suspending system was also evaluated in Figure 19. 
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Figure 19. Drug substance glass transition temperature versus onset of crystallization time for 
33.3% drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS 
+ 5 mM HCl. Note the red circle color coding denoting a crystallization time of less than 20 
minutes, the orange triangle color coding for crystallization time between 20 minutes and 3 
hours, and the green diamond color coding denoting a crystallization time of greater than 3 
hours. 
 
Both the glass transition temperature of the amorphous dispersion and the glass transition 
temperature of the drug substance show lack of correlation with the onset of crystallization in our 
model suspension systems.  This may be due to the measurements being taken under dry 
conditions.  In the hydrophilicity section of this chapter a correction will be made for the 
amorphous dispersion glass transition temperature at 100% RH, and this value will show 
superior predictive capability and physical meaning. 
The next thermal property to be evaluated was melting temperature as shown in Figure 
20. 
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Figure 20. Melting temperature versus onset of crystallization time for 33.3% drug/66.7% 
HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM HCl. Note 
the red circle color coding denoting a crystallization time of less than 20 minutes, the orange 
triangle color coding for crystallization time between 20 minutes and 3 hours, and the green 
diamond color coding denoting a crystallization time of greater than 3 hours. 
 
For melting temperature, compounds with a melting temperature above 180 °C have a 
greater propensity to crystalize than those with melting temperatures below 180 °C (of these 8 
compounds, 5 model compounds crystallize within 20 minutes, 2 compounds crystallize between 
20 minutes and 3 hours, and 1 compound crystallizes after 3 hours).  This parameter may serve 
as a surrogate to crystal lattice energy11,48-51.  This data trend suggests that compounds with a 
high melting temperature have an elevated potential to crystallize in our model amorphous 
suspension system.  This is consistent with numerous literature references which describe the 
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difficulty in solubilizing high melting temperature compounds and the potential for these 
compounds to crystallize11,48-51. This is also consistent with classical nucleation theory29,30. 
 After determining the utility of melting temperature as a predictive parameter in 
predicting the rate of onset of crystallization in the model suspension system, enthalpy of fusion 
(Figure 21), entropy of fusion (Figure 22) and the Gibbs Free Energy via the Hoffman Equation 
(Figure 23) were evaluated.   
 
 
Figure 21. Enthalpy of fusion versus onset of crystallization time for 33.3% drug/66.7% 
HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM HCl. Note 
the red circle color coding denoting a crystallization time of less than 20 minutes, the orange 
triangle color coding for crystallization time between 20 minutes and 3 hours, and the green 
diamond color coding denoting a crystallization time of greater than 3 hours. 
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Figure 22. Entropy of fusion versus onset of crystallization time for 33.3% drug/66.7% 
HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM HCl. Note 
the red circle color coding denoting a crystallization time of less than 20 minutes, the orange 
triangle color coding for crystallization time between 20 minutes and 3 hours, and the green 
diamond color coding denoting a crystallization time of greater than 3 hours. 
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Figure 23. Gibbs Free Energy (Hoffman Equation) versus onset of crystallization time for 33.3% 
drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM 
HCl. Note the red circle color coding denoting a crystallization time of less than 20 minutes, the 
orange triangle color coding for crystallization time between 20 minutes and 3 hours, and the 
green diamond color coding denoting a crystallization time of greater than 3 hours. 
 
 Enthalpy of fusion, and Gibbs free energy (Hoffman Equation) versus onset of 
crystallization time figures, fail to provide additional predictive value relative to melting 
temperature.  However, it is interesting to note that compounds with entropy of fusion values of 
greater than 0.1 kJ/K*mole all have delayed crystallization kinetics relative to model compounds 
with less crystal lattice entropy.  This suggests that a crystal lattice with a high degree of entropy 
(propensity for disorder) would be beneficial in delaying the onset of crystallization for these 
model suspension systems.  This logical finding is consistent with numerous literature references 
on classical nucleation theory29,30. 
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Having established the value of melting temperature as a thermal predictive parameter for 
rank ordering the propensity of model compounds to crystallize in the model suspension system, 
it was important to evaluate whether the ratio of melting temperature to glass transition 
temperature (Tm/Tg) would help improve or refine the model. It has been suggested in the 
literature55 that this ratio could be predictive of physical stability of amorphous systems.  Figure 
24 shows these data, however there is not additional predictive value relative to use of melting 
temperature alone.  One potential explanation for this lack of correlation could stem from the 
difference between the glass transition temperature of a suspended amorphous dispersion (a three 
component system of drug substance, polymer and water) versus the glass transition temperature 
of the drug substance alone. 
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Figure 24. Ratio of melting temperature to glass transition temperature (Tm/Tg) versus onset of 
crystallization time for 33.3% drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 
0.5% MC + 0.25% SLS + 5 mM HCl. Note the red circle color coding denoting a crystallization 
time of less than 20 minutes, the orange triangle color coding for crystallization time between 20 
minutes and 3 hours, and the green diamond color coding denoting a crystallization time of 
greater than 3 hours. 
 
In addition to the thermal models shown previously in this thesis, cyclic DSC, as 
originally described by Baird and Taylor has become widely used for rank ordering the 
crystallization tendency of pharmaceutical compounds62.  Figure 25 describes the cyclic DSC 
process.  First, the sample is heated in the DSC to beyond the melting temperature of the 
compound and held isothermal for several minutes to allow the model compound to fully melt.  
The compound is then cooled at a controlled rate to room temperature.  If the compound 
undergoes crystallization during the cooling process, the compound would be classified as a 
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strong crystallizer/class I compound.  After cooling to room temperature the compound is the 
reheated at a controlled rate to above the melting temperature of the compound.  If the compound 
crystallizes during this reheating phase of the cycle, the compound is classified as a moderate 
crystallizer/class II compound.  If the compound fails to crystallize during this process, the 
compound is classified as a weak crystallizer/class III compound.  This process is outlined in 
Figure 25. 
 
  
Figure 25. A cyclic DSC diagram describing how compounds are classified into strong, moderate 
and weak crystallizing compounds. 
 
Each of the 24 model compounds was classified as a class I, II or III compound via cyclic 
DSC experiments.  For the strong crystallizers, this model shows all compounds crystallize 
within 3 hours in the model suspension conditions.  However, the model fails to predict the 
number of class II and class III compounds that crystallize in the model suspension system.  This 
inability of the model to predict which class II and class III compounds crystallize could be 
explained in three different ways, likely stemming from the dry (lack of moisture) nature of this 
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model.  This predictive deficiency could be due to the inability of the model to account for the 
potential of the drug to leach out of the amorphous dispersion particle and into the bulk 
suspending media.  Once dissolved in the bulk suspending media, the compound has 
considerably more molecular mobility than is present in the DSC pan.  In addition, this could be 
due to the inability of the model to account for interactions with moisture such as anti-solvent 
effects or potential to form hydrates.  Lastly, several compounds may undergo thermal 
degradation due to the stress of the heat/cool/heat cycle.  This could lead to sample impurities, 
which could either serve as crystallization inhibitors, or could undergo their own thermal events 
which could be misinterpreted62. 
 
 
Figure 26.  Cyclic DSC class as a predictive tool for crystallization of 33.3% drug/66.7% 
HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM HCl. Note 
the red color coding denoting a crystallization time of less than 20 minutes, the orange color 
coding for crystallization time between 20 minutes and 3 hours, and the green color coding 
denoting a crystallization time of greater than 3 hours. 
 
After detailed uni-variate analysis of the thermal descriptors including glass transition 
temperature of the model amorphous dispersion, glass transition temperature of the model drug 
Class I 
Compounds 
Class II 
Compounds Class III 
Compounds 
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substance, the melting temperature of the model drug, the entropy of fusion, enthalpy of fusion 
and Gibbs free energy of the model drug substance, as well as the cyclic DSC classification and 
the drug substance melting temperature/glass transition temperature ratio, it was determined that 
melting temperature and entropy of fusion provide the greatest utility in predicting which 
compounds which will crystallize in the model suspension system.  Melting temperature 
provides the most utility for two reasons.  First, this is a relatively easy experimental parameter 
to determine and is readily available in the drug discovery space, assuming crystalline material is 
available.  Second, the clear delineation of compounds above and below 180 °C shows the 
critical risk of crystallization which stems from high melting temperature compounds.  Entropy 
of fusion helps predict which compounds will have delayed crystallization rates despite having a 
high melting temperature, or which compounds may have accelerated crystallization rates despite 
having a low melting temperature. 
 
c.) Hydrophilicity Descriptors: 
 
Uni-variate analysis was attempted for the various hydrophilicity descriptors including 
Log P, water solubility, the general solubility equation, platform vehicle solubility, and moisture 
uptake at 90% humidity. The upcoming figures display these correlations. 
Log P was evaluated as a property that would describe the lipophilicity of each model 
compound (Figure 27). 
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Figure 27. Log P versus onset of crystallization time for 33.3% drug/66.7% HPMCAS-LF spray 
dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM HCl. Note the red circle color 
coding denoting a crystallization time of less than 20 minutes, the orange triangle color coding 
for crystallization time between 20 minutes and 3 hours, and the green diamond color coding 
denoting a crystallization time of greater than 3 hours. 
 
Compounds with a Log P above 3 show a reduced time to crystallize in our model 
amorphous suspension system than do compounds with a Log P below 3.  This parameter may 
infer interactions with the suspending media.  If the primary crystallization mechanism first 
requires dissolution into the bulk suspending media (Failure Mode 1), a largely aqueous/polar 
environment, than it may be hypothesized that this rate of dissolution/leaching may be delayed 
for more compounds with a higher Log P.  
Water solubility for the model compounds may be a critical parameter as dissolution into 
the bulk suspending media may be required for the crystallization mechanism for these model 
suspensions.  To this end, a calculated water solubility, from the general solubility equation, and 
literature (See Appendix 3 for reference data) water solubility numbers for each of the 24 model 
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compounds were obtained.  The plots for these solubility values versus crystallization kinetics 
for each model suspension appear in Figures 28 and 29. 
 
Figure 28. Calculated water solubility (GSE) versus onset of crystallization time for 33.3% 
drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM 
HCl. Note the red circle color coding denoting a crystallization time of less than 20 minutes, the 
orange triangle color coding for crystallization time between 20 minutes and 3 hours, and the 
green diamond color coding denoting a crystallization time of greater than 3 hours. 
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Figure 29. Water solubility (mg/mL) versus onset of crystallization time for 33.3% drug/66.7% 
HPMCAS-LF spray dried amorphous dispersions in 0.5% methocellulose + 0.25% SLS + 5 mM 
HCl. Note the red circle color coding denoting a crystallization time of less than 20 minutes, the 
orange triangle color coding for crystallization time between 20 minutes and 3 hours, and the 
green diamond color coding denoting a crystallization time of greater than 3 hours. 
 
There is limited correlation between the calculated or literature water solubility and the 
propensity for each model compound to crystallize in the model amorphous suspension system.  
However, a trend can be observed, where compounds with solubility values greater than 0.1 
mg/mL have an increased propensity to crystallize.  This may be due to an enhanced dissolution 
rate from the amorphous dispersion, in which compound must first dissolve out of the suspended 
amorphous spray dried dispersion and into the bulk suspending vehicle prior to crystallization 
(failure mode 1).  Attempts at improving the correlation between the amorphous suspension 
physical stability and solubility measurements were made by measuring the equilibrium 
0.1
1
10
100
0.0001 0.001 0.01 0.1 1
Water Solubility (mg/mL)
O
ns
et
of
 C
ry
st
al
liz
at
io
n 
fo
r 3
3.
3%
 d
ru
g 
/ 6
6.
7%
 H
PM
CA
S-
L 
Di
sp
er
sio
ns
 in
 0
.5
%
 M
C 
+ 
0.
25
%
 S
LS
 +
 5
m
M
 H
Cl
 a
s 
De
te
ct
ed
 b
y 
PX
RD
 a
nd
 P
LM
 (h
r)
51 
 
solubility of each compound in the platform suspending vehicle (Figure 30).  Unfortunately this 
fails to improve the correlation between solubility and suspension physical stability. 
 
 
Figure 30. Platform vehicle solubility (mg/mL; 48 hr/25 °C) versus onset of crystallization time 
for 33.3% drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% 
SLS + 5 mM HCl. Note the red circle color coding denoting a crystallization time of less than 20 
minutes, the orange triangle color coding for crystallization time between 20 minutes and 3 
hours, and the green diamond color coding denoting a crystallization time of greater than 3 
hours. 
 
Given that the suspending medium (0.5% methocellulose + 0.25% SLS + 5 mM HCl) is 
acidified with HCl, and the suspended polymer (HPMCAS-LF) is enteric with an apparent pKa 
of 5.055, it is vital to consider whether the ionization state (pKa) of each model compound is 
predictive of suspension physical stability in the model system.  Table 4 compares the pKa and 
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Ionization state to onset of crystallization time for the model system.  However, note the lack of 
correlation between pKa or ionization state and rate of crystallization. 
 
Table 4. pKa and ionization state versus physical stability for each model amorphous dispersion. 
Note the red color coding denoting a crystallization time of less than 20 minutes, the orange 
color coding for crystallization time between 20 minutes and 3 hours, and the green color coding 
denoting a crystallization time of greater than 3 hours.  
Acid/ Base 
Classification 
Model 
Compound Crystal Rate Category pKa Ionization 
Zwitterion Piroxicam < 20 minutes 1.8, 5.1 partially 
Weak Base 
Nevirapine < 20 minutes 2.8 partially 
Ritonavir > 3 hours 2.8 partially 
Ketoconazole > 3 hours 2.9 partially 
Tolazamide < 20 minutes 3.6 partially 
Itraconazole > 3 hours 3.7 partially 
Omeprazole 20 min - 3 hours 4 unionized 
Chlorpropamide < 20 minutes 4.3 unionized 
Felodipine 20 min - 3 hours 5.4 unionized 
Clotrimazole > 3 hours 6.6 unionized 
Bifonazole > 3 hours 6.7 unionized 
Miconazole > 3 hours 6.7 unionized 
Aprepitant 20 min - 3 hours 9.7 unionized 
Celecoxib > 3 hours 11.1 unionized 
Telaprevir > 3 hours 11.9 unionized 
Efavirenz > 3 hours 12.5 unionized 
Weak Acid 
Indomethacin > 3 hours 4.5 unionized 
Indoprofen < 20 minutes 5.8 unionized 
Telmisartan 20 min - 3 hours 3.5 unionized 
Neutral 
Griseofulvin < 20 minutes x unionized 
Torcetrapib > 3 hours x unionized 
Clofoctol > 3 hours x unionized 
Carbamazepine < 20 minutes x unionized 
Fenofibrate < 20 minutes x unionized 
 
Another factor to consider, in regards to amorphous materials and interactions with 
moisture, is the hygroscopicity of each amorphous dispersion.  The 24 model amorphous 
dispersions can be rank ordered in hygroscopicity by determining the peak amount of moisture 
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uptake of each of the amorphous dispersions after undergoing a moisture sorption/desorption 
isotherm (details appear in chapter 2).  An example moisture sorption isotherm appears below for 
a 33.3% Aprepitant/66.7% HPMCAS-LF spray dried amorphous solid dispersion.  The 
compilation plot of moisture uptake versus suspension physical stability appears in Figure 31. 
 
 
Figure 31. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Aprepitant/66.7% HPMCAS-LF 
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Figure 32. Moisure weight percent gain at 25 °C/90% RH for 33.3% wt active amorphous 
dispersions in HPMCAS-LF. Note the red color coding denoting a crystallization time of less 
than 20 minutes, the orange color coding for crystallization time between 20 minutes and 3 
hours, and the green color coding denoting a crystallization time of greater than 3 hours. 
 
There is a trend between the hygroscopity of the amorphous dispersion and the physical 
stability of the model system.  For amorphous dispersions in which the weight gain is less than 
5.5%, 10 amorphous dispersions have onset of crystallization times >3 hours, 2 have times 
between 20 minutes and 3 hours, and only 2 have onset of crystallization times less than 20 
minutes. 
The value of the hygroscopicity data increases when it is used with the amorphous 
dispersion glass transition temperature to calculate the Tg,dispersion,100%RH. This parameter has 
significant predictive value (Figure 33).  As the Tg,dispersion,100%RH  rises above 30 °C, the material 
can be assumed to be in the glassy state at room temperature.  In this case 7 of the 8 compounds 
show onset of crystallization times which exceed 3 hours and only 1 compound shows an onset 
of crystallization time which is between 20 minutes and 3 hours.  No compounds show onset of 
crystallization times below 20 minutes. It can be hypothesized that both failure mode 1 and 2 
would show a decreased rate of crystallization as Tg,dispersion,100%RH rises above 30 °C.  In failure 
mode 1, the dissolution of drug from the glass into the bulk could be hypothesized to be slower 
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than that of a super cooled liquid.  For failure mode 2, the crystallization in the amorphous 
dispersion particle would be slower for a glass than a super cooled liquid. 
 
Figure 33. Tg,dispersion,100%RH  (°C) versus onset of crystallization time for 33.3% drug/66.7% 
HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM HCl. Note 
the red circle color coding denoting a crystallization time of less than 20 minutes, the orange 
triangle color coding for crystallization time between 20 minutes and 3 hours, and the green 
diamond color coding denoting a crystallization time of greater than 3 hours. 
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Chapter 4: Multi-variate Analysis of Descriptors 
 
 This chapter focuses on the value of building a multi-variate model to predict the 
amorphous suspension physical stability of a spray dried amorphous dispersion based upon the 
physicochemical properties of the selected model compound. From this a 2-tiered model emerges 
in which first, the model considers the humidity adjusted glass transition temperature of the 
amorphous dispersion (Tg,dispersion,100% RH).  For compounds where Tg,dispersion,100% RH is >30 °C  the 
amorphous dispersion is in a glassy state and is protected from crystallization within 3 hours of 
preparation.  For compounds where Tg,dispersion,100% RH is <30 °C the amorphous dispersion is a 
super cooled liquid at room temperature and is not kinetically protected from rapid 
crystallization. For these compounds analysis of melting temperature/ entropy of fusion (must be 
<5500 K2*mol/KJ to be predicted stable) and molecular weight x LogP (must be >1000 to be 
predicted stable) can be used to successfully predict a 3 hour shelf-life. The resulting decision 
tree is outlined in Figure 1.  
 
 
Figure 1. Decision tree for assessing the physical stability of a model compound spray dried to 
form an amorphous dispersion at 33.3% drug load in HPMCAS and suspended in 0.5% 
methocellulose + 0.25% SLS + 5 mM HCl.  
  
 
Uni-variate analysis of the available data suggests there is a relationship between 
physicochemical descriptors of each of the model molecules and the rate of crystallization in the 
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model amorphous suspension system.  However, there is the opportunity to combine these 
descriptors in two dimensional, three dimensional and even multi-dimensional models. 
Five parameters, from uni-variate analysis, which show trends with suspension 
crystallization rates are melting temperature, entropy of fusion, Log P, molecular weight and 
Tg,dispersion,100% RH.   
First, these results suggest that amorphous dispersions in the glassy state (Tg,dispersion,100% 
RH  < 30°C; Figure 33) are more stable than those which are super cooled liquids (Tg,dispersion,100% 
RH   >30°C; Figure 33).  Next, it becomes evident that compounds in the super cooled liquid state 
are more likely to nucleate and crystallize, by either failure mode 1 or failure mode 2, if they are 
small (<400 dalton; Figure 11), lipophilic (Log P <3; Figure 27), high melting temperature (> 
180 °C; Figure 20), low entropy of fusion (<0.08 kJ/K*mole; Figure 22) compounds, which is 
consistent with classical nucleation theory29,30.   
Several figures can be constructed considering 2-4 of these parameters (melting 
temperature, entropy of fusion, lipophilicity and molecular weight) for the molecules in the super 
cooled liquid state.  A simplistic 2-D diagram is a melting temperature versus Log P diagram.  
These parameters were selected because they showed a predictive trend in the uni-variate 
analysis. 
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Figure 34. Melting temperature and Log P versus onset of crystallization time for 33.3% 
drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% SLS + 5 mM 
HCl. Note the red circle color coding denoting a crystallization time of less than 20 minutes, the 
orange triangle color coding for crystallization time between 20 minutes and 3 hours, and the 
green diamond color coding denoting a crystallization time of greater than 3 hours. 
 
While Figure 34 illustrates the importance of melting temperature and Log P on the 
crystallization rate of amorphous suspensions, and differentiates rapid crystallizing compounds 
(top left) and slow crystallizing compounds (bottom right), it over estimates the crystallization 
potential for Telaprevir and Aprepitant, which are high entropy of fusion compounds.  This 
model also underestimates the importance of the low entropy of fusion for Felodipine, 
Fenofibrate and Omeprazole.  Once the Y-Axis is converted to melting temperature/entropy of 
fusion versus Log P Figure 35 is generated. 
Nevirapine
Piroxicam
Griseofulvin
Chlorpropamide
Tolazamide
Indoprofen
Aprepitant
Telaprevir
Ketoconazole
Indomethacin Celecoxib
Clotrimazole
Ritonavir
Felodipine
Carbamazepine
Fenofibrate
Omeprazole
Torcetrapib
0
50
100
150
200
250
300
0 1 2 3 4 5 6 7 8 9
Log P
M
el
tin
g 
 T
em
pe
ra
tu
re
 (°
C)
59 
 
 
Figure 35. Melting temperature/entropy of fusion and Log P versus onset of crystallization time 
for 33.3% drug/66.7% HPMCAS-LF spray dried amorphous dispersions in 0.5% MC + 0.25% 
SLS + 5 mM HCl. Note the red circle color coding denoting a crystallization time of less than 20 
minutes, the orange triangle color coding for crystallization time between 20 minutes and 3 
hours, and the green diamond color coding denoting a crystallization time of greater than 3 
hours. 
 
 In the plot shown in Figure 35  melting temperature, entropy of fusion and Log P are 
incorporated into the model.  However, this model fails to incorporate the importance of 
molecular weight on crystallization rate.  This can be accomplished by converting the x-axis into 
Log P x Molecular Weight as shown in Figure 36. 
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 Figure 36. Melting temperature/entropy of fusion vs. molecular weight x Log P versus 
onset of crystallization time for 33.3% drug/66.7% HPMCAS-LF spray dried amorphous 
dispersions in 0.5% MC + 0.25% SLS + 5 mM HCl. Note the red circle color coding denoting a 
crystallization time of less than 20 minutes, the orange triangle color coding for crystallization 
time between 20 minutes and 3 hours, and the green diamond color coding denoting a 
crystallization time of greater than 3 hours. 
 
 Figure 36 is able to capture 4 critical descriptors (melting temperature, entropy of fusion, 
molecular weight and Log P) of nucleation onto one 2-D plot.  Compounds in the upper left hand 
corner will rapidly crystalline (< 3 hours) in the model system, as these compound are 
characterized by a high melting temperature, low entropy of fusion, low Log P and low 
molecular weight.  Compounds in the lower right hand corner will be slower (> 3 hours) to 
crystallize in the model system because these compounds are characterized by a low melting 
temperature, a high entropy of fusion, a high Log P and a high molecular weight.  From these 
data, a region of Figure 36, in which melting temperature/entropy of fusion is < 5500 K2mol/kJ 
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and Molecular Weight x Log P is > 1000 can be established as a ‘physical stability zone’ in 
which compounds are likely to have greater than 3 hours of physical stability within the model 
system. 
 A two tiered model in which the calculated glass transition temperature of the amorphous 
dispersion at 100% RH (Tg,dispersion,100% RH), to differentiate amorphous dispersions in the glassy 
state from the super cooled liquid state is first considered, and the melting temperature/ entropy 
of fusion versus the molecular weight x Log P for the compounds in the super cooled liquid state 
is considered next, and this model will correctly predict the relative physical stability of 22 of the 
24 model compounds.  This two staged approach can be thought of as first applying theory 
related to amorphous systems and the glass transition to determine whether the material is in a 
glassy or super cooled liquid state, followed by evaluating descriptors which are relevant to 
classical nucleation theory for those amorphous dispersions which are in the super cooled liquid 
state. 
 Two outliers emerge in the data analysis.  The first outlier is Telmisartan.  Telmisartan 
has a high Tg,dispersion,100% RH  of 57 °C, which one would predict to be stable in suspension.  
However, the melting temperature of Telmisartan is 269 °C, and the melting temperature/entropy 
of fusion for Telmisartan is 5542 K2mol/kJ, which suggests that any drug substance, which is 
able to partition into the bulk suspending vehicle, as per failure mode 1, would rapidly 
crystallize. This strong driving force for crystallization is the likely reason that Telmisartan 
appears in the moderate crystallization rate group (20 minutes – 3 hours) despite having a 
Tg,dispersion,100% RH  of 57 °C. 
 The second outlier in the analysis is Fenofibrate.  Fenofibrate would be predicted to have 
a crystallization time > 3 hours based upon the melting temperature/entropy of fusion vs. Log P x 
molecular weight 2-D plot.  However, Fenofibrate crystallizes in less than 20 minutes.  The 
leading hypothesis for this result centers around the symmetry plane that divides Fenofibrate 
(Figure 37). 
 
Figure 37. Structure of Fenofibrate 
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The current model fails to incorporate shape or symmetry of a molecule.  Therefore, the 
model may under predict the crystallization rate of molecules which are linear with a symmetry 
plane, and may rapidly assemble into a crystal lattice. 
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Chapter 5: Conclusions 
 
Suspensions of spray dried amorphous dispersions are a valuable tool for enhancing the 
exposure of poorly soluble compounds in preclinical animal models.  However, limitations in 
drug supply and time/cost of manufacture in the drug discovery space make it desirable to 
predict the probability of obtaining a stable (free from detectable crystallization) suspension prior 
to synthesis, scale-up and processing of a candidate compound.   
A model system was prepared for 24 model compounds and interrogated for the onset of 
crystallization.  The crystallization kinetics for each system were monitored and compared to 
physicochemical descriptors for each model compound.   
A 2-tiered multivariate model was assembled.  This model first considers the calculated 
glass transition temperature of the amorphous dispersion at 100% RH (Tg,dispersion,100% RH) to, 
delineate amorphous dispersions in the glassy state from the super cooled liquid state, and 
assumes amorphous dispersions in the glassy state will have a physical stability greater than 3 
hours in the model system. Second, the model considers the melting temperature/entropy of 
fusion versus the molecular weight * Log P for the compounds in the super cooled liquid state.  
From this 2-D plot a physical stability zone where melting temperature/entropy of fusion is < 
5500 K2mol/kJ and molecular weight x Log P is > 1000 is estabilished. 
This model is useful in its simplicity and its ability to correctly predict the physical 
physical stability of 22 out of 24 of the model compounds evaluated.  The model also ties 
empirical physical physical stability data back to literature on amorphous materials and the 
importance of glass transition temperature and to classical nucleation theory. 
Future opportunities exist to expand upon this research.  While a platform dispersion 
polymer, drug loading and vehicle were held constant in this work, additional work could be 
conducted to probe the impact of these parameters on the kinetics of crystallization for 
suspensions of amorphous dispersions. 
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Appendix 1: Spray Dried Dispersion Characterization Data 
 
This appendix contains the data used to characterize the spray dried dispersion prior to 
conducting suspension crystallization studies.  Each sample of spray dried dispersion was 
determined to be amorphous by three orthogonal techniques, PXRD (i.e., lack of crystalline 
reflections), mDSC (i.e., lack of a crystalline melt)  and PLM (i.e., lack of birefringence) 
characterization.  mDSC was used to confirm that the material was single phase (i.e., appearance 
of one glass transition temperature). 
In addition to PXRD, mDSC and PLM, select samples were analyzed by HPLC (to 
confirm potency), TGA (to gain insight into residual solvent/moisture) and LLS (to determine 
typical particle size distributions for these spray dried materials). 
 
 
Figure 38. Characterization of spray dried 33.3% Nevirapine/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 39. Characterization of spray dried 33.3% Piroxicam/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
 
 
Figure 40. Characterization of spray dried 33.3% Griseofulvin/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 41. Characterization of spray dried 33.3% Chlorpropamide/66.7% HPMCAS-LF by 
PXRD, mDSC and PLM. 
 
 
Figure 42. Characterization of spray dried 33.3% Tolazamide/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 43. Characterization of spray dried 33.3% Indoprofen/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
 
 
Figure 44. Characterization of spray dried 33.3% Fenofibrate/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 45. Characterization of spray dried 33.3% Carbamazepine/66.7% HPMCAS-LF by 
PXRD, mDSC and PLM. 
 
 
Figure 46. Characterization of spray dried 33.3% Telmisartan/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 47. Characterization of spray dried 33.3% Aprepitant/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
 
 
Figure 48. Characterization of spray dried 33.3% Felodipine/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 49. Characterization of spray dried 33.3% Omeprazole/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
 
 
Figure 50. Characterization of spray dried 33.3% Bifonazole/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 51. Characterization of spray dried 33.3% Telaprevir/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
 
 
Figure 52. Characterization of spray dried 33.3% Ketoconazole/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 53. Characterization of spray dried 33.3% Miconazole/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
 
 
Figure 54. Characterization of spray dried 33.3% Itraconazole/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 55. Characterization of spray dried 33.3% Indomethacin/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
 
 
Figure 56. Characterization of spray dried 33.3% Clofoctol/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 57. Characterization of spray dried 33.3% Ritonavir/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
 
 
Figure 58. Characterization of spray dried 33.3% Efavirenz/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 59. Characterization of spray dried 33.3% Clotrimazole/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
 
 
Figure 60. Characterization of spray dried 33.3% Torcetrapib/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
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Figure 61. Characterization of spray dried 33.3% Celecoxib/66.7% HPMCAS-LF by PXRD, 
mDSC and PLM. 
 
 
 
Figure 62. Particle Size data for spray dried amorphous dispersions of Nevirapine, Piroxicam, 
Griseofulvin and Chlorpropamide in HPMCAS-LF at 33.3% DL. 
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Figure 63. Particle Size data for spray dried amorphous dispersions of Celecoxib, Fenofibrate, 
Indomethacin, and Indoprofen in HPMCAS-LF at 33.3% DL. 
 
 
Figure 64. Particle Size data for spray dried amorphous dispersions of Itraconazole and 
Miconazole in HPMCAS-LF at 33.3% DL. 
 
 The particle size data from 10 representative spray dried batches (Figure 62, 63 and 64) 
suggest that the spray dried dispersion has a relatively narrow particle size distribution with the 
mean particle size typically falling between 5 and 15 μm. 
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Figure 65. TGA data for spray dried amorphous dispersions of Piroxicam, Fenofibrate, 
Miconazole, Clotrimazole, Tolazamide, Indoprofen and Clofoctol in HPMCAS-LF at 33.3% DL. 
 
 
Figure 66. TGA data for spray dried amorphous dispersions of Chlorpropamide, Bifonazole, 
Ketoconazole, Griseofulvin, Indoprofen, Celecoxib and Intraconazole in HPMCAS-LF at 33.3% 
DL. 
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The TGA data from 14 representative spray dried batches (Figure 65 and 66) suggests 
that the spray dried dispersion has a relatively low levels of residual moisture/organic solvent.  
Levels are typically < 1.5%. 
 
Table 5. Potency Determination for 6 Batches of Spray Dried Dispersions. 
 
The potency data from 6 representative spray dried batches (Table 5) suggests that the 
spray dried dispersion typically has a potency within 2% of the target potency by weight. 
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Appendix 2: Amorphous Suspension Physical Stability Data  
The range for the onset of crystallization of each compound was determined by PXRD 
and PLM.  The upcoming data supports each assigned range in Figure X. 
 
 
 
Figure 67. PXRD and PLM data for spray dried Nevirapine/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 20 minutes. 
 
 
 
Figure 68. PXRD and PLM data for spray dried Piroxicam/HPMCAS-LF (33.3% Drug Loading) 
suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 20 minutes. 
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Figure 69. PXRD and PLM data for spray dried Griseofulvin/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 20 minutes. 
 
 
Figure 70. PXRD and PLM data for spray dried Chlorpropamide/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 20 minutes. 
 
Figure 71. PXRD and PLM data for spray dried Tolazamide/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 20 minutes. 
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Figure 72. PXRD and PLM data for spray dried Indoprofen/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 20 minutes. 
 
 
Figure 73. PXRD and PLM data for spray dried Fenofibrate/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 20 minutes. 
 
Figure 74. PXRD and PLM data for spray dried Carbamazepine/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 20 minutes. 
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Figure 75. PXRD and PLM data for spray dried Telmisartan/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 20 and 40 minutes. 
 
 
Figure 76. PXRD and PLM data for spray dried Aprepitant/HPMCAS-LF (33.3% Drug Loading) 
suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 20 and 60 minutes. 
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Figure 77. PXRD and PLM data for spray dried Felodipine/HPMCAS-LF (33.3% Drug Loading) 
suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 40 and 60 minutes. 
 
 
Figure 78. PXRD and PLM data for spray dried Omeprazole/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 1 and 1.5 hours. 
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Figure 79. PXRD and PLM data for spray dried Bifonazole/HPMCAS-LF (33.3% Drug Loading) 
suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 4 and 8 hours. 
 
 
 
Figure 80. PXRD and PLM data for spray dried Telaprevir/HPMCAS-LF (33.3% Drug Loading) 
suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 8 and 24 hours. 
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Figure 81. PXRD and PLM data for spray dried Ketoconazole/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 8 and 24 hours. 
 
 
Figure 82. PXRD and PLM data for spray dried Miconazole/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 24 and 48 hours. 
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Figure 83. PXRD and PLM data for spray dried Itraconazole/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 24 and 48 hours. 
 
 
 
Figure 84. PXRD and PLM data for spray dried Indomethacin/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 24 and 48 hours. 
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Figure 85. PXRD and PLM data for spray dried Clofoctol/HPMCAS-LF (33.3% Drug Loading) 
suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 48 and 72 hours. 
 
 
 
Figure 86. PXRD and PLM data for spray dried Ritonavir/HPMCAS-LF (33.3% Drug Loading) 
suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 72 and 96 hours. 
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Figure 87. PXRD and PLM data for spray dried Efavirenz/HPMCAS-LF (33.3% Drug Loading) 
suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 72 and 96 hours. 
 
 
Figure 88. PXRD and PLM data for spray dried Clotrimazole/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 96 and 168 hours. 
93 
 
 
 
Figure 89. PXRD and PLM data for spray dried Torcetrapib/HPMCAS-LF (33.3% Drug 
Loading) suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 96 and 168 hours. 
 
 
Figure 90. PXRD and PLM data for spray dried Celecoxib/HPMCAS-LF (33.3% Drug Loading) 
suspended in 0.5% MC + 0.25% SLS + 5 mM HCl after 168 hours. 
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Appendix 3: Multi-variate Descriptors Data and References 
The data to support thermal and hydrophilicity analysis for each compound is provided in 
Appendix 3.  Note that structural data is not provided, because no experiments were conducted to 
obtain these values. 
 
Thermal data for thesis model compounds: 
 A summary of the thermal data used in this thesis appears in Table 2.  The glass transition 
values for the dry amorphous dispersions can be found in the characterization data in Appendix 
1.  As mentioned in the thesis, the Gibbs Free Energy values were calculated using equation 3.   
 A large portion of the data appears previously in the literature by Baird62.  This data is 
summarized in Table 6. 
 
Table 6. Reference thermal data from the Baird publication62. 
Model Compound 
Melting 
Temperature 
(deg C) 
Enthalpy 
Fusion 
(kJ/mol) 
Entropy 
Fusion 
(kJ/K*mol) 
Tg, 
Drug 
(deg C) 
Cyclic 
DSC 
Class 
Griseofulvin 218 39.1 0.079 89 1 
Indoprofen 212 36.0 0.074 50 1 
Chlorpropamide 124 27.4 0.069 16 1 
Tolazamide 172 43.4 0.098 18 2 
Bifonazole 151 39.2 0.092 17 2 
Clofoctol 88 35.1 0.097 -4 2 
Celecoxib 163 37.4 0.086 58 2 
Itraconazole 168 57.6 0.129 58 3 
Miconazole 160 32.7 0.091 1 3 
Ketoconazole 150 52.9 0.125 45 3 
Clotrimazole 145 31.8 0.076 30 3 
Indomethacin 161 37.6 0.086 45 3 
Ritonavir 121 60.4 0.153 50 3 
Felodipine 145 31.0 0.074 45 3 
Carbamazepine 190 25.5 0.055 61 1 
Fenofibrate 80 33.0 0.093 -19 3 
Omeprazole 159 26.6 0.062 45 3 
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Piroxicam thermal data: 
 The cyclic DSC of piroxicam can be found in Figure 91.  The additional data for 
Piroxicam was obtained from the literature63,64. 
 
 
Figure 91. Cyclic DSC characterization of Piroxicam. 
 
Telaprevir thermal data: 
 All thermal data for Telaprevir was generated from Figure 92, 93 and 94. 
 
 
Figure 92. DSC characterization of Telaprevir. 
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Figure 93. Modulated DSC characterization of Telaprevir. 
 
 
 
Figure 94. Cyclic DSC characterization of Telaprevir. 
 
Efavirenz thermal data: 
 Efavirenz thermal data was generated by Figure 95 and 96 and by review of the literature 
from Ilevbare and Taylor19. 
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Figure 95. DSC characterization of Efavirenz. 
 
 
Figure 96. Cyclic DSC characterization of Efavirenz. 
 
Aprepitant thermal characterization data: 
 Aprepitant thermal data was generated in Figure 97 and 98.  Note that the glass transition 
temperature of aprepitant is taken from the cyclic DSC experiment due to the difficulty in 
generating amorphous aprepitant by other means. 
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Figure 97. DSC characterization of Aprepitant. 
 
 
 
Figure 98. Cyclic DSC characterization of Aprepitant. 
 
 
 
253.16°C
252.81°C
92.14J/g
-12
-10
-8
-6
-4
-2
0
H
e
at
 F
lo
w
 (
W
/g
)
0 50 100 150 200 250 300
Temperature (°C)
Sample: Aprepitant
Size:  1.9000 mg
Method: Ramp
DSC
File: X:...\APREPITANT STARTING MATERIAL.003
Operator: JDO
Run Date: 22-Apr-2013 14:20
Instrument: DSC Q2000 V24.4 Build 116
Exo Up Universal V4.7B TA Instruments
-6
-4
-2
0
2
H
e
a
t 
F
lo
w
 (
W
/g
)
0 50 100 150 200 250 300
Temperature (°C)
Sample: Aprepitant Cyclic DSC
Size:  7.9400 mg
Method: Heat/Cool/Heat
DSC
File: APREPITANT CYCLIC STARTING MATERIAL.0
Operator: JDO
Run Date: 24-Apr-2013 09:27
Instrument: DSC Q2000 V24.4 Build 116
Exo Up Universal V4.7B TA Instruments
99 
 
Torcetrapib thermal data: 
 Torcetrapib thermal data was generated in Figure 99, 100 and 101.   
 
 
Figure 99. DSC characterization of Torcetrapib. 
 
 
Figure 100. Modulated DSC characterization of Torcetrapib. 
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Figure 101. Cyclic DSC characterization of Torcetrapib. 
 
Telmisartan thermal characterization data: 
 Telmisartan thermal data was generated by Figure 102 and 103 and by review of the 
literature65. 
 
 
Figure 102. DSC characterization of Telmisartan. 
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Figure 103. Cyclic DSC characterization of Telmisartan. 
 
Nevirapine thermal characterization data: 
 Thermal data for Nevirapine was obtained via literature search66 and Figure 104. 
 
 
Figure 104. Cyclic DSC characterization of Nevirapine 
 
 
Omeprazole thermal characterization data: 
 Omeprazole thermal data was generated by Figure 105, 106 and 107. 
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Figure 105. DSC characterization of Omeprazole. 
 
 
Figure 106. Modulated DSC characterization of Omeprazole. 
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Figure 107. Cyclic DSC characterization of Omeprazole. 
 
Hydrophilicity data for thesis model compounds: 
 A summary of the Hydrophilicity data used in this thesis appears in Table 3.   
 
Log P values: 
 Log P values for griseofulvin, chlorpropamide, indoprofen, tolazamide, bifonazole, 
clofoctol, celecoxib, itraconazole, miconazole, ketoconazole, clotrimazole, indomethacin, and 
felodipine can be found in a publication by Baird/Taylor62. Log P values for ritonavir and 
efavirenz can be found in a publication by Ilevbare/Taylor19.  Log P values for nevirapine, 
piroxicam, aprepitant, telmisartan, carbamazepine, fenofibrate and omeprazole are available at 
the Canadian Drug Bank Database67. The Log P value for torcetrapib is available at the Look 
Chem Online Database68.  The Log P value for telaprevir is available in a publication by 
Kwong69. 
 
pKa values: 
 All pKa values listed, for ionizable molecules come from the Canadian Drug Bank 
Database67, with the exception of indoprofen which is available in the literuatre70. 
 
 
-4
-2
0
2
H
e
a
t 
F
lo
w
 (
W
/g
)
20 40 60 80 100 120 140 160 180
Temperature (°C)
Sample: Omeprazole Cyclic DSC
Size:  10.5000 mg
Method: Heat/Cool/Heat
DSC
File: OMEPRAZOLE CYCLIC STARTING MATERIAL
Operator: JDO
Run Date: 24-Apr-2013 12:21
Instrument: DSC Q2000 V24.4 Build 116
Exo Up Universal V4.7B TA Instruments
104 
 
Water solubility values: 
 All listed water solubility values were taken from the Canadian Drunk Bank67. 
 
General Solubility Equation Data: 
 All values were calculated using equation 6. 
 
Percent w/w Gain at 90% RH: 
 The following data was used to calculate the wt. % gain of each amorphous dispersion at 
90% RH. 
 
 
Figure 108. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Aprepitant/66.7% HPMCAS-LF. 
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Figure 109. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Bifonazole/66.7% HPMCAS-LF. 
 
 
Figure 110. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Carbamazepine/66.7% HPMCAS-LF. 
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Figure 111. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Celecoxib/66.7% HPMCAS-LF. 
 
 
Figure 112. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Clorpropamide/66.7% HPMCAS-LF. 
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Figure 113. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Clofoctol/66.7% HPMCAS-LF. 
 
 
Figure 114. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Clotrimazole/66.7% HPMCAS-LF. 
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Figure 115. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Efavirenz/66.7% HPMCAS-LF. 
 
 
Figure 116. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Felodipine/66.7% HPMCAS-LF. 
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Figure 117. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Fenofibrate/66.7% HPMCAS-LF. 
 
 
 
Figure 118. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Griseofulvin/66.7% HPMCAS-LF. 
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Figure 119. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Indomethacin/66.7% HPMCAS-LF. 
 
 
 
Figure 120. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Indoprofen/66.7% HPMCAS-LF. 
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Figure 121. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Itraconazole/66.7% HPMCAS-LF. 
 
 
Figure 122. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Ketoconazole/66.7% HPMCAS-LF. 
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Figure 123. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Miconazole/66.7% HPMCAS-LF. 
 
 
 
Figure 124. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Nevirapine/66.7% HPMCAS-LF. 
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Figure 125. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Omeprazole/66.7% HPMCAS-LF. 
 
 
Figure 126. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Piroxicam/66.7% HPMCAS-LF. 
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Figure 127. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Ritonavir/66.7% HPMCAS-LF. 
 
 
 
Figure 128. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Telaprevir/66.7% HPMCAS-LF. 
 


















98
100
102
104
106
W
e
ig
h
t (
%
)
0 20 40 60 80 100
Relative Humidity (%)
Sorption Isotherm
              Adsorption–––––––
              Desorption–––––––
Sample: Rit33LF
Size:  3.1480 mg
Method: Adsorption\Desorption
TGA
File: RIT33LF DVS
Operator: JDO
Run Date: 18-Apr-2013 06:02
Instrument: TGA Q5000 V3.10 Build 258
Universal V4.7B TA Instruments


















96
98
100
102
104
W
e
ig
h
t (
%
)
0 20 40 60 80 100
Relative Humidity (%)
Sorption Isotherm
              Adsorption–––––––
              Desorption–––––––
Sample: Telap33LF
Size:  5.8100 mg
Method: Adsorption\Desorption
TGA
File: TELAP33LF DVS
Operator: JDO
Run Date: 16-Apr-2013 09:16
Instrument: TGA Q5000 V3.10 Build 258
Universal V4.7B TA Instruments
115 
 
 
Figure 129. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Telmisarten/66.7% HPMCAS-LF. 
 
 
Figure 130. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Tolazamide/66.7% HPMCAS-LF. 
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Figure 131. Moisture sorption isotherm (25 °C) for a spray dried amorphous dispersion of 33.3% 
Torcetrapib/66.7% HPMCAS-LF. 
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